Objectives: To systematically review and provide estimates of the minimal important change (MIC) and difference (MID) for outcome tools in people with knee osteoarthritis (OA) after non-surgical interventions. A systematic review.
Data Sources: MEDLINE, CINAHL, Web of Science, Scopus and Cochrane databases were searched up to 21 September 2021.
Eligibility Criteria: We included studies that calculated MIC and MID using any calculation method including anchor, consensus and distribution methods, for any knee OA outcome tool after non-surgical interventions.
Data Extraction And Synthesis: We extracted reported MIC, MID and minimum detectable change (MDC) estimates. We used quality assessment tools appropriate to the studies' methods to screen out low-quality studies. Values were combined to produce a median and range, for each method.
Results: Forty-eight studies were eligible (anchor-k=12, consensus-k=1 and distribution-k=35). MIC values for 13 outcome tools including Knee injury and Osteoarthritis Outcome Score (KOOS)-pain, activities of daily living (ADL), quality of life (QOL) and Western Ontario and McMaster Universities Arthritis Index (WOMAC)-function were estimated using 5 high-quality anchor studies. MID values for 23 tools including KOOS-pain, ADL, QOL and WOMAC-function, stiffness and total were estimated using 6 high-quality anchor studies. One moderate quality consensus study reported MIC for pain, function and global assessment. MDC values from distribution method estimates for 126 tools including KOOS-QOL and WOMAC-total were estimated using 38 good-to-fair-quality studies.
Conclusion: Median MIC, MID and MDC estimates were reported for outcome tools in people with knee OA after non-surgical interventions. The results of this review clarify the current understanding of MIC, MID and MDC in the knee OA population. However, some estimates suggest considerable heterogeneity and require careful interpretation.
Prospero Registration Number: CRD42020215952.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201231 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2022-063026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic Drug Monitoring of High-dose Sulbactam in Pediatric Patients: Preliminary Data From a Prospective Observational Pharmacokinetic Study.
Pediatr Infect Dis J
October 2024
From the Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine.
Background: Rates of carbapenem-resistant Acinetobacter baumannii are rising in Thailand. Although high-dose (HD) sulbactam is recommended for treating carbapenem-resistant A. baumannii infections, data on plasma sulbactam concentrations in children are limited.
View Article and Find Full Text PDFInducing programmed cell death trough MazEF system to combat Staphylococcus aureus: A non-antibiotic treatment candidate.
PLoS One
December 2024
Department of Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran.
The aim of the present study was to evaluate the role of extracellular death factor (EDF) derived from Escherichia coli in the induction of programmed cell death (PCD) in methicillin-resistant and -susceptible Staphylococcus aureus (MRSA and MSSA). The confirmation of bacterial strains as well as the minimum inhibitory concentration (MIC) test were performed according to CLSI, 2022. The extraction and efficacy determination of EDF as well as the CFU assessment were done.
View Article and Find Full Text PDFTarget Attainment and Population Pharmacokinetics of Cefazolin in Patients with Invasive Infections: A Prospective Cohort Study.
Antibiotics (Basel)
September 2024
Division of Internal Medicine, University Hospital Basel, 4031 Basel, Switzerland.
This study aimed to determine cefazolin target attainment in patients with invasive () infections and to develop a population pharmacokinetic (PK) model. Adult patients with invasive infections treated with cefazolin bolus infusions were included. Unbound and total trough and mid-dose cefazolin concentrations were measured, and strain-specific MICs were determined.
View Article and Find Full Text PDFEarly detection of myocardial iron overload in patients with β-thalassemia major using cardiac magnetic resonance T1 mapping.
Magn Reson Imaging
December 2024
Pediatric Hematology Oncology and BMT Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Faculty of Medicine Ain Shams University Research Institute-Clinical Research Center (MASRI-CRC), Faculty of Medicine, Ain Shams University, Cairo, Egypt. Electronic address:
Article Synopsis
- The T2* technique for measuring myocardial iron content has limitations in detecting early myocardial iron overload, prompting researchers to explore T1 mapping as a more effective alternative.
- A study involving 32 β-thalassemia major patients showed that T1 mapping could differentiate between patients and healthy controls, identifying cases of high myocardial iron content that T2* missed.
- Incorporating T1 mapping into the evaluation process enhances the detection of myocardial iron overload, potentially improving treatment strategies and reducing heart-related complications in patients.
The minimal important change (MIC) and minimal clinically important difference (MCID) of the patient and observer scar assessment scale (POSAS) 2.0.
Burns
November 2024
Burn Centre, Maasstad Hospital, Rotterdam, the Netherlands; Trauma Research Unit, Department of Surgery, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands.
Background: The Patient and Observer Scar Assessment Scale (POSAS) is frequently used to assess scar quality after burns. It is important to be aware of the minimal important change (MIC) and the minimal clinically important difference (MCID) to establish if a POSAS score represents a clinically relevant change or difference. The aim of this study is to explore the MIC and MCID of POSAS version 2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!